drugset
drugset / Trial / NCT04245397

Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome

NCT04245397 ↗

Phase 1 Recruiting 151 enrolled Syntrix Biosystems, Inc. AdventHealth · collabEmory University · collabH. Lee Moffitt Cancer Center and Research Institute · collabMayo Clinic · collabMontefiore Medical Center · collabNational Cancer Institute (NCI) · collabNational Heart, Lung, and Blood Institute (NHLBI) · collabSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · collabUniversity of Miami · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

This study will determine the safety profile, maximum tolerated dose (MTD), dose-limiting toxicities (DLT), and recommended Phase 2 dose (RP2D) of SX-682 in the treatment of patients with Myelodysplastic Syndromes (MDS).

Timeline

Start
2020-06-30
Primary completion
2028-03
Completion
2029-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Decitabine Small molecule — Oral
Subject SX-682 Small molecule 25 mg Oral
Subject SX-682 Small molecule 50 mg Oral
Subject SX-682 Small molecule 100 mg Oral
Subject SX-682 Small molecule 200 mg Oral
Subject SX-682 Small molecule 400 mg Oral

Indications

myelodysplastic syndrome